简介:摘要目的通过分析鳃耳综合征患儿及家系成员的临床表现和基因序列,明确其生物学致病原因。方法收集我国云南地区1例鳃耳综合征患儿及家系成员的临床资料,提取先证者及其家系成员的外周血基因组DNA,对406个耳聋相关易感基因全部外显子及其侧翼序列进行高通量测序,并对突变位点进行Sanger测序验证分析。结果该家系包括3代9人,其中4人表现为听力下降、耳前瘘管和鳃裂瘘,符合鳃耳综合征的临床诊断。先证者及其母亲耳廓畸形,内耳发育畸形,肾脏未见异常。系谱分析显示,该家系遗传方式为常染色体显性遗传。基因检测显示在所有发病成员的EYA1基因上均发现一个未见报道的杂合突变位点,c.1255delT(p.C419Vfs*12),家系内该变异与耳聋表型共分离,且此突变为移码突变,导致终止密码子提前出现。根据美国医学遗传学与基因组学学会(American College of Medical Genetics and Genomics,ACMG)指南初步判定为致病性变异,家系中表型正常成员及100名健康人中均未发现该位点突变。家系中3名成员存在EYA1 c.403G>A(p.G135S)杂合突变,该突变导致第135号氨基酸由甘氨酸变异为丝氨酸,为错义突变,其中2名成员表型正常,ACMG指南判定该变异临床意义未明。结论EYA1 c.1255delT是该家系鳃耳综合征患者的主要分子病因,家系内患病个体间临床表现具有异质性,鳃耳综合征的诊断需将表型和基因测序密切结合。
简介:摘要目的探讨1个疑似鳃-耳综合征家系的临床表型,寻找该家系的可能致病原因,为其临床诊断提供依据。方法应用目标序列捕获技术对先证者进行耳聋基因的筛查,找到可疑致病变异,并用Sanger测序对家系成员进行验证。结果遗传性耳聋基因筛查检测到先证者EYA1 c.1627C>T(p.Gln543Ter)无义变异;Sanger测序证实该家系中4例有鳃-耳综合征临床表型的患者均系EYA1 c.1627C>T(p.Gln543Ter)变异杂合子。根据美国医学遗传学与基因组学学会遗传变异分类标准与指南,EYA1 c.1627C>T(p.Gln543Ter)变异判定为致病性变异( PVS1+PS+PP3+PP4)。结论EYA1基因c.1627C>T(p.Gln543Ter)变异可能为该家系患者的致病原因,基因检测结果可以为其临床诊断提供依据。
简介:摘要通过家系调查、临床检查和遗传学特征分析,对一个鳃-耳-肾综合征家系的临床表型及致病原因进行系统研究。该家系表现为常染色体显性遗传,4位先证者均表现为听力损失、鳃裂瘘管、耳前瘘管、肾异常中的两种及以上的混合症状,症状轻重不等。遗传性耳聋基因芯片检测未发现常见的耳聋基因突变,sanger法基因检测结果显示4位先证者的EYA1基因c.889C>T(p.R297X)突变,为无义突变且均为杂合变异,根据美国医学遗传学与基因组学学会(American College of Medical Genetics and Genomics, ACMG)指南初步判定为致病性变异,现结合文献报道如下。
简介:AbstractBackground:Emerging evidence indicates that the sineoculis homeobox homolog 1-eyes absent homolog 1 (SIX1-EYA1) transcriptional complex significantly contributes to the pathogenesis of multiple cancers by mediating the expression of genes involved in different biological processes, such as cell-cycle progression and metastasis. However, the roles of the SIX1-EYA1 transcriptional complex and its targets in colorectal cancer (CRC) are still being investigated. This study aimed to investigate the roles of SIX1-EYA1 in the pathogenesis of CRC, to screen inhibitors disrupting the SIX1-EYA1 interaction and to evaluate the efficiency of small molecules in the inhibition of CRC cell growth.Methods:Real-time quantitative polymerase chain reaction and western blotting were performed to examine gene and protein levels in CRC cells and clinical tissues (collected from CRC patients who underwent surgery in the Department of Integrated Traditional and Western Medicine, West China Hospital of Sichuan University, between 2016 and 2018, n = 24). In vivo immunoprecipitation and in vitro pulldown assays were carried out to determine SIX1-EYA1 interaction. Cell proliferation, cell survival, and cell invasion were determined using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, clonogenic assay, and Boyden chamber assay, respectively. The Amplified Luminescent Proximity Homogeneous Assay Screen (AlphaScreen) method was used to obtain small molecules that specifically disrupted SIX1-EYA1 interaction. CRC cells harboring different levels of SIX1/EYA1 were injected into nude mice to establish tumor xenografts, and small molecules were also injected into mice to evaluate their efficiency to inhibit tumor growth.Results:Both SIX1 and EYA1 were overexpressed in CRC cancerous tissues (for SIX1, 7.47 ± 3.54 vs.1.88 ± 0.35, t = 4.92, P = 0.008; for EYA1, 7.61 ± 2.03 vs. 2.22 ± 0.45, t = 6.73, P = 0.005). The SIX1/EYA1 complex could mediate the expression of two important genes including cyclin A1 (CCNA1) and transforming growth factor beta 1 (TGFB1) by binding to the myocyte enhancer factor 3 consensus. Knockdown of both SIX1 and EYA1 could decrease cell proliferation, cell invasion, tumor growth, and in vivo tumor growth (all P < 0.01). Two small molecules, NSC0191 and NSC0933, were obtained using AlphaScreen and they could significantly inhibit the SIX1-EYA1 interaction with a half-maximal inhibitory concentration (IC50) of 12.60 ± 1.15 μmol/L and 83.43 ± 7.24 μmol/L, respectively. Administration of these two compounds could significantly repress the expression of CCNA1 and TGFB1 and inhibit the growth of CRC cells in vitro and in vivo.Conclusions:Overexpression of the SIX1/EYA1 complex transactivated the expression of CCNA1 and TGFB1, causing the pathogenesis of CRC. Pharmacological inhibition of the SIX1-EYA1 interaction with NSC0191 and NSC0933 significantly inhibited CRC cell growth by affecting cell-cycle progression and metastasis.
简介:你知道不莱梅吗?噢——它是一个美丽快乐的地方。不莱梅在哪儿呢?噢——有梦想的地方就有不莱梅。没错儿,不莱梅这个地方,早就存在于“很久很久以前”的童话里了……